Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

NETWORK × Astrocytoma × vorasidenib × Clear all

Phase

Status

Sponsor Class

INDUSTRY 2 OTHER 1 NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Interventions

Temozolomide 12 Radiotherapy 10 Lomustine 5 Carboplatin 5 Carmustine 4 Vincristine 3 Granulocyte Colony-Stimulating Factor 3 Filgrastim 3 Etoposide 3 imetelstat 2 etoposide phosphate 2 Thiotepa 2 Radiotherapy, Intensity-Modulated 2 Radiotherapy, Conformal 2 Procarbazine 2 Peripheral Blood Stem Cell Transplantation 2 Drug Therapy 2 Chemotherapy, Adjuvant 2 vorasidenib 1 veliparib 1 transforming growth factor(alpha)-Pseudomonas aeruginosa exotoxin (38) 1 selinexor 1 sargramostim 1 palbociclib 1 lonafarnib 1 laromustine 1 emvododstat 1 carmustine, poliferprosan 20 drug combination 1 azurin (50-77) 1 Vinorelbine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06809322 2026-02-17

VIGOR

European Organisation for Research and Treatment of Cancer - EORTC

Phase 3 Recruiting

Astrocytoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡